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Abstract
Screening of an inhibitor library targeting kinases and
epigenetic regulators identified several molecules having
antiproliferative synergy with extraterminal domain (BET)
bromodomain (BD) inhibitors (JQ1, OTX015) in triple-
negative breast cancer (TNBC). GSK2801, an inhibitor of
BAZ2A/B BDs, of the imitation switch chromatin remodel-
ing complexes, and BRD9, of the SWI/SNF complex, dem-
onstrated synergy independent of BRD4 control of P-TEFb–
mediated pause-release of RNA polymerase II. GSK2801 or
RNAi knockdown of BAZ2A/B with JQ1 selectively displaced
BRD2 at promoters/enhancers of ETS-regulated genes. Addi-
tional displacement of BRD2 from rDNA in the nucleolus
coincided with decreased 45S rRNA, revealing a function of
BRD2 in regulating RNA polymerase I transcription. In 2D
cultures, enhanced displacement of BRD2 from chromatin
by combination drug treatment induced senescence. In
spheroid cultures, combination treatment induced cleaved
caspase-3 and cleaved PARP characteristic of apoptosis in
tumor cells. Thus, GSK2801 blocks BRD2-driven transcrip-
tion in combination with BET inhibitor and induces apo-
ptosis of TNBC.
Implications: Synergistic inhibition of BDs encoded in
BAZ2A/B, BRD9, and BET proteins induces apoptosis of TNBC
by a combinatorial suppression of ribosomal DNA transcrip-
tion and ETS-regulated genes.
Introduction
Inhibitors of the bromodomain (BD) and extraterminal
domain (BET) epigenetic readers have shown preclinical promise
in multiple types of cancer, notably in acute myelogenous
leukemia (AML) where BET proteins play a critical role in main-
taining transcription of MYC (1–3). BRD2/3/4 interact with
acetyl-lysine residues on histone tails and nonhistone proteins
via their BDs. Their regulatory function is, in part, attributed to the
ability of BRD4 to associate with and recruit the positive tran-
scription elongation factor (P-TEFb) complex via interactions
involving its unique C-terminal domain (CTD). P-TEFb is a
multisubunit complex composed of CDK9 and its regulatory
subunit cyclin T1. P-TEFb promotes productive gene transcription
in concert with additional transcriptional coactivators (Mediator
complex) and chromatin-modifying enzymes [CREB-binding
protein (CBP)/p300]. BRD4 is the best characterized BET family
member, which recruits and activates the P-TEFb complex leading
to transcriptional elongation through CDK9-catalyzed phosphor-
ylation of serine 2 in the CTD of RNA polymerase II (Pol II;
refs. 4, 5).
In addition to inhibition of tumor growth as single agents, BET
BD inhibitors (BETi) have been shown to block adaptive resis-
tance in combination with inhibitors targeting receptor tyrosine
kinases and the MEK–ERK and PI3K pathways (6–9). Inhibition
of these signaling networks results in genome-wide enhancer
formation involving the seeding of BRD4, MED1, H3K27 acety-
lation, and CBP/p300 that drives P-TEFb–dependent transcrip-
tional adaptation (6). BETi blocks enhancer remodeling and
prevents P-TEFb–dependent transcriptional adaptive reprogram-
ming, making the action of the kinase inhibitors more durable
and actually preventing or reversing resistance (6).
Preclinical models of breast cancer are generally sensitive to
inhibition of BET BD-dependent transcription (7, 10, 11),
specifically triple-negative breast cancer (TNBC; ref. 12), which
is a heterogeneous and aggressive disease defined by the absence
of targetable receptors for estrogen and progesterone, and
HER2 (13, 14). Clinical trials are currently testing the efficacy of
BETi in treating TNBC, other solid tumors, and hematologic
malignancies (ClinicalTrials.gov). Both BRD2 and BRD4 are
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HCC1806, WHIM12, and MDA-MB-468 cells were main-
tained in RPMI1640 medium (Gibco, Thermo Fisher Scientific)
supplemented with 10% FBS, 1,000 U/mL Penicillin and
1 mg/mL Streptomycin. MDA-MB-231 and SUM-159 cells were
maintained in DMEM/F12 1:1 medium (Gibco, Thermo
Fisher Scientific) supplemented with 5% FBS, 5 mg/mL insulin,
1 mg/mL hydrocortisone, 1,000 U/mL penicillin, and 1 mg/mL
streptomycin. SUM-149(þ) and WHIM2 cells were maintained
in HuMEC medium with defined media supplements
(Gibco, Thermo Fisher Scientific) and supplemented with
5% FBS, 1,000 U/mL penicillin, and 1 mg/mL streptomycin.
SUM-149(þ) cells used in this study contain EpCAMþ/CD45fþ
cells, which were isolated via FACS from the heterogeneous
parental SUM-149 cell line.
Cell line authentication
All cell lineswereobtained from the Lineberger Comprehensive
Cancer Center as well as collaborating labs. Whim2 andWhim12
cell lines derived from PDXs have been whole-exome sequenced
and RNA-sequenced for reference. All other cell lines used in this
study have been authenticated by the Johns Hopkins Genetics
Core Resources Facility using their short-tandem repeat testing.
Cell lines are annually tested in the lab forMycoplasma. Cell lines
were passaged no longer than one month for all experiments
performed.
Compounds
Information on compounds used in screening and subsequent
validation experiments is listed in Supplementary Data File 1. BI-
9564 (catalog. no. S8113) was obtained from Selleckchem and
BAZ2-ICR (catalog. no. SML1276) was obtained from Sigma-
Aldrich.
Synergy screening
The optimal dose range for JQ1, OTX015, or CPI-637 was
determined for each cell line screened across half-log doses. JQ1
and OTX015 screens were performed in 6  6 dose-response
matrices. MDA-MB-231, SUM-149(þ), and WHIM12 cell
lines were treated with 3 nmol/L–1 mmol/L JQ1. HCC1806,
WHIM2, and MDA-MB-468 cell lines were treated with
10 nmol/L–3 mmol/L JQ1. MDA-MB-231 cells were dosed with
10 nmol/L–3 mmol/L OTX015. All CPI-637 screens were per-
formed in 5  6 dose-response matrices. MDA-MB-231,
HCC1806, WHIM2, and WHIM12 cells were dosed with
100 nmol/L–10 mmol/L CPI-637 in half-log doses. Cells were
seeded in 384-well plates using a BioTek microplate dispenser.
The following day cells were dosed with drug using a Beckman
Coulter Biomek FX instrument. The screening library was tested
for growth inhibition alone or in combination across 6 doses
of the screening library: 10 nmol/L, 100 nmol/L, 300 nmol/L,
1 mmol/L, 3 mmol/L, and 10 mmol/L. Bortezomib (1 mmol/L)
was included as a positive control or 0.1% DMSO as a negative
control for growth inhibition on each plate. Plates were incu-
bated at 37C for 96 hours and lysed by adding 10-mL CellTiter-
Glo Reagent (Promega, catalog. no. G7570) to 50-mL cell
media. Luminescence was measured using a PHERAstar FS
instrument and growth inhibition was calculated relative to
DMSO-treated wells.
overexpressed in basal-like TNBC, but the functional distinctions 
in the mechanisms by which BRD2 and BRD4 regulate transcrip-
tion independent of P-TEFb activation remain poorly defined.
We performed dose-dependent drug synergy screens against 
inhibitors targeting the BET BD to define novel combinatorial 
strategies that selectively enhanced growth inhibition by BETi in 
TNBC. Of particular interest was the novel drug synergy we 
discovered between inhibitors targeting additional families of 
BDs encoded in CBP/p300, BAZ2A/B, and BRD9. GSK2801, an 
inhibitor of the BDs of BAZ2A (TIP5), BAZ2B, and BRD9 
(BD-containing protein 9) showed little or no growth inhibition 
as a single agent, yet combined treatment with BETi resulted in 
strong growth inhibition of TNBC. BRD9, whose BD binds 
GSK2801 with a lower affinity than the BD of BAZ2A/B, is a 
member of the SWI/SNF regulatory complex that regulates chro-
matin remodeling and transcription. Bromodomain adjacent to 
zinc finger domain (BAZ2) proteins function as regulatory sub-
units that pair with one of two ATPases, SMARCA1 (SNF2L) or 
SMARCA5 (SNF2H), to form the core of imitation switch chro-
matin remodeling complexes (ISWI; ref. 15). BAZ2A binds 
SMARCA5 to form the nucleolar remodeling complex (NoRC), 
which maintains a pool of heterochromatic ribosomal DNA 
(rDNA; ref. 16). NoRC function is important not only to temper 
the amount of rDNA copies accessible for transcription, of which 
there are hundreds in a given mammalian cell, but also to 
maintain genomic stability of these highly repetitive regions. This 
protective function of the NoRC also extends to centromeres and 
telomeres (17, 18). Little is known about the function of BAZ2B; it 
was recently reported that BAZ2B forms stable complexes with 
both ATPases making it a novel ISWI regulatory subunit (19).
The TCGA pan-cancer dataset indicates BAZ2A and BAZ2B are 
not frequently mutated across cancer with the exception of uterine 
corpus endometrial carcinoma where both BAZ2A and BAZ2B are 
mutated in greater than 10% of tumors. Increased expression of 
BAZ2A/B mRNA is observed across several tumor types including 
thyroid carcinoma and AML. A superenhancer enriched for 
H3K27Ac was recently identified proximal to the BAZ2B gene in 
AML (20). BAZ2B is consistently highly expressed in AML with no 
change in copy number, suggesting epigenetic mechanisms of 
BAZ2A/B overexpression. BRD9 is also not frequently mutated in 
the TCGA pan-cancer dataset but is significantly amplified in lung 
cancers. BRD9 has also been implicated in driving AML growth as 
a subunit of the SWI/SNF complex via regulation of MYC 
transcription (21).
Our screening results provide a series of synergistic drug com-
binations to achieve durable inhibition of TNBC cell proliferation 
with BET or CBP/p300 BD inhibitors. These data highlight a 
unique mechanism of synergy between the BAZ2/BRD9 BD 
inhibitor GSK2801 and BETi. Drug synergy was not observed 
between GSK2801 and other inhibitors of P-TEFb transcriptional 
activation including CBP/p300 and CDK9 inhibitors, indicating a 
mechanism of synergy unrelated to pause-release of Pol II. 
Instead, loss of BRD2 from chromatin following combined 
GSK2801 and BETi blocked ETS-regulated gene transcription in 
the nucleoplasm as well as nucleolar transcription of rRNA. These 
findings support distinct functional roles of BRD2 in regulating 
nucleoplasmic and nucleolar transcription relative to other BET 
family proteins. Furthermore, these results reveal unique adaptive 
mechanisms of BRD2 on chromatin in response to BETi, which are 
amenable to coinhibition of BAZ2/BRD9 BDs to induce apoptosis 
in 3D-spheroid cultures of TNBC.
transcriptome coordinates using Salmon 0.60 (27). Isoform data
were collated to single-gene IDsusing theRpackagebiomaRt (28),
and abundance estimateswere upper quartile normalized usingR.
Raw and processed RNA sequencing (RNA-seq) data have been
uploaded to GEO (accession no. GSE116919).
Gene set enrichment analysis
Gene set enrichment analysis (GSEA) was run on drug-treated
RNA-seq datasets according to instructions at http://software.
broadinstitute.org/gsea/index.jsp. All Hallmark, GO, and Onco-
genic Signature gene sets were analyzed using the following
parameters: number of permutations, 1,000; permutation type,
gene_set; enrichment statistic, weighted; metric for ranking genes,
Signal2Noise; gene set maximum size, 500; gene set minimum
size, 15.
ChIP-seq analysis
ChIP-seq datasets were aligned using Bowtie v1.1.2 (29) to
the human reference genome (hg19) or to a single copy of the
ribosomal DNA repeat (GenBank: U13369.1). Alignments were
performed using the following parameters: -v 2 – m 1. All
analysis was performed using RefSeq (30) hg19 human gene
annotations. Read density was normalized to the total
number of million mapped reads (rpm). Data was normalized
by subtracting read density of the input chromatin from the
ChIP read density. HCC1806 and SUM-159 input datasets
were used from (6), GEO accession no. GSE87424. MACS
2.2.2.20160309 (31) and HMCan v1.28 (32) were used to
call enriched regions. We found that MACS was not calling
peaks in the regions with high copy-number variation
and therefore used HMCan to call peaks in these regions.
MACS was run using default settings. HMCan was run with
narrow peak calling configuration file with no blacklisted
regions. Peaks within 12.5 kb of each other were stitched as
described previously (33). For comparative analysis across drug
treatments, union peaks were defined, which represent a col-
lection of peak regions across all the treatment datasets in a
project. Peak classification was performed as described in (6)
and python code generated in the laboratory for ChIP-seq
analysis is available at https://github.com/darshansinghunc/
chippeakanalysis.
A peak in dataset A was considered overlapped by dataset B if
40%of the length of the peak in dataset Awas covered by a peak in
dataset B.
ChIP-seq data visualization. For ribosomalDNA alignments, reads
were normalized to the total number of readsmapped to the hg19
reference genome per sample. Read counts were recorded in
250 bp bins and data were plotted using R. For fold change plots
a floor of 5 rpm was created to avoid artificially high fold change
values.
ChIP-seq density tracks in Fig. 3L–O and Supplementary
Fig. S4F and S4G were created by normalizing data to the total
number of mapped reads. Read counts were plotted using
Python.
Box-and-whisker plots for ChIP-seq datasets were generated
using peaks with greater than or equal to 5 rpmdensity in, at least,
one treatment condition. Paired t testswere performed tomeasure
statistical differences between samples.
All metagene plots and heatmaps were generated using
HOMER (34). A total of 25 bp bins were used to generate all
Drug synergy analysis
Drug synergy scores were generated using the SynergyFinder 
package 1.6.1 (22). Bliss, Loewe, highest single agent (HSA), and 
zero interaction potency (ZIP) scores were calculated without 
baseline correction and using default parameters with the excep-
tion that Emin was specified as 0 and Emax as 100. Synergy was 
assessed across individual doses of each library compound to 
generate six possible scores per compound. To be considered a hit, 
a given compound had to generate a positive mean synergy score 
for at least 1 dose tested in 5 of 6 (for JQ1 screening data) or 3 of 
4 (for CPI-637 screening data) cell lines screened. Hits were then 
ranked by the mean of all synergy scores produced in the drug 
combination matrix. Synergy scores represent the percent growth 
inhibition induced by a drug combination, which exceeded the 
expected growth inhibition. Expected growth inhibition was 
calculated on the basis of the effect of each drug as a single agent.
Chromatin immunoprecipitation and library preparation
Chromatin immunoprecipitation (ChIP) experiments were 
performed as described in (6). Briefly, approximately 1  107 
cells per immunoprecipitation were cross-linked 10 minutes at 
room temperature in 1.1% formaldehyde. Nuclear extracts were 
sonicated 15 cycles (30-second pulse, 30-second cooling) using a 
Bioruptor Pico (Diagenode). Samples were tumbled overnight at 
4C with 10-mg antibody conjugated to protein A Dynabeads 
(Thermo Fisher Scientific). Following reverse cross-linking and 
RNase/proteinase K treatment, DNA was eluted from beads and 
purified using Qiagen MinElute PCR purification columns. Chro-
matin immunoprecipitation coupled with deep sequencing 
(ChIP-seq) libraries were prepared using the KAPA HyperPrep 
Kit according to the manufacturer's instructions. For each set of 
experimental samples an equal amount of DNA was used to 
generate libraries (between 10–50 ng depending on experiment). 
Samples were indexed using Illumina TruSeq indexed adapters. 
Dual size selection was performed following 12–18 cycles 
PCR amplification. Samples were 12-plexed and single-end 75 bp 
reads were generated using an Illumina NextSeq-500. Raw and 
processed ChIP-seq datasets have been uploaded to GEO (acces-
sion no. GSE116919).
RNA-sequencing
Four microgram of total RNA was isolated from cells using the 
Qiagen RNeasy Plus Kit. Sequencing libraries were prepared using 
the KAPA stranded mRNA-seq kit according to the manufacturer's 
instructions with the exception that libraries were amplified 10 
cycles by PCR. Samples were indexed using Illumina TruSeq 
indexed adapters. Samples were 12-plexed and run on an Illumina 
NextSeq-500 to produce 75-cycle single-end reads.
RNA-sequencing analysis
RNA-seq datasets of TNBC patient tumors and cell lines used 
in Fig. 1C and D are deposited in dbGaP (phs001405.v1.p1) and 
GEO (accession no. GSE87424), respectively. Data was generated 
and processed as cited in (6). Briefly datasets were aligned to the 
human reference genome (hg19_M_rCRS) using MapSplice (23), 
sorted and indexed using SAMtools v1.2 (24), and transcript 
abundance estimates were generated using the RSEM expecta-
tion-maximization algorithm (25).
For drug-treated datasets used in the rest of the manuscript, 
QC-passed reads were aligned to the human reference genome 
(hg38) using STAR 2.4.2a (26) and reads were translated to

plots surrounding  2 kb of the annotated tss or peak center.
Heatmaps were visualized using Java Treeview (35).
Motif enrichment analysis. HOMER was employed to define
motifs enriched at BRD2-occupied genomic loci. All BRD2
peaks greater than or equal to 5 rpm in DMSO control
samples were used for each cell line analyzed. Default para-
meters were used to search a 200 bp window surrounding
peak centers.
Tumor spheroids
Tumor cells expressing red fluorescent protein (RFP) were
plated in low-adhesion round-bottom 96-well plates as mono-
cultures or were cocultured with reduction mammoplasty fibro-
blasts (RMF) expressing GFP. For SUM-149(þ) spheroids, 5,000
tumor cells were seeded perwell ormixed at a 1:1 ratiowith RMFs.
ForWHIM12 spheroids, 1,000 tumor cells weremixedwith 2,000
RMFs per well. Spheroids were given 48 hours to form before
beginning drug treatment. At endpoint, cell fluorescence was
imaged using an Evos FL Auto 2 instrument. Following imaging,
spheroids were lysed in CellTiter-Glo 3D (Promega, catalog. no.
G9681) by adding 50-mL reagent to 150-mL cellmedia. Plates were
rotated at 150 rpm for 30 minutes before luminescence was read
using a PHERAstar FS.
Results
High-throughput identification of synergistic drug
combinations with BETi in TNBC
A 175 compound, small-molecule inhibitor library targeting
protein kinases and epigenetic modifiers was used in 6  6
dose-response matrices to screen for drug synergy in combina-
tion with BD inhibitors (Fig. 1A). Library compounds were
selected on the basis of target diversity, as well as indication of
clinical success, and suitable FDA-approval (Supplementary
Data File 1). We screened six TNBC cell lines representing
TNBC basal-like and claudin-low molecular subtypes (36, 37)
against JQ1, a BETi. The cell lines displayed a range of baseline
sensitivities to JQ1 (IC50s ranged from 37.4 nmol/L to 1.1
mmol/L; Supplementary Fig. S1A). Synergy was assessed using
multiple computational models (22) including HSA, the Loewe
additivity model (Loewe), the Bliss independence model
(Bliss), and the ZIP (Supplementary Data File 2; ref.38). Com-
mon hits identified in all cell lines across all synergy models
(Fig. 1B; Supplementary Fig. S1B) were validated with an
additional BETi, OTX015 (39), in the MDA-MB-231 cell line
(Supplementary Data File 3).
Inhibition of previously identified targets: MEK1/2-ERK1/2
[trametinib and selumetinib (MEKi), SCH772984 (ERKi)],
P-TEFb [HY-16462 and flavopiridol (CDK9i), SGC-CBP30
(CBP/p300i; ref 6)], and Aurora kinase (alisertib and barasertib;
ref. 11), validated the synergy screen (Fig. 1B; Supplementary
Fig. S1C–S1F). Among the other top hits was PF-3758309 that
selectively targets PAK4 with higher potency than other PAK
family members. PF-3758309 caused cell shape changes and
diminished adherence in 2D culture of multiple TNBC cell lines.
Western blots showed no reduction in pERK1/2 or pAKT follow-
ing combination PAK/BET BD inhibition (Supplementary
Fig. S1G), suggesting loss of cell number in 2D screens was due
to cytoskeletal changes. PF-3758309 was not further pursued
because clinical trials for this compound have been terminated
and other PAKi have not progressed in patient trials despite
significant numbers of studies in preclinical models (Clinical-
Trials.gov).
Of particular interest from the screen hits was the novel drug
synergy observed between BETi and GSK2801, an inhibitor of
BAZ2A and BAZ2B BDs with partial activity against the BRD9
BD. BAZ2A and BAZ2B are members of the BD adjacent to zinc
finger domain (BAZ) protein family and contain a PHD
domain and homologous BD (40). We observed similar expres-
sion levels by RNA-seq of BAZ2A and BAZ2B between primary
TNBC patient tumors (dbGaP: phs001405.v1.p1) and cell lines
(Fig. 1C and D). BAZ2A is expressed more highly than BAZ2B in
TNBC cell lines at an average RSEM read count of 2,233
compared with 451, respectively. Knockdown via RNAi of
BAZ2A and B in combination with JQ1 resulted in significant
growth inhibition (Fig. 1E–G; Supplementary Fig. S1H), con-
sistent with the screening results. We further validated syner-
gistic growth inhibition with combination GSK2801 and JQ1
in a panel of TNBC cell lines (Fig. 1H).
In addition to binding the BDs of BAZ2A/B, GSK2801 has
reported binding activity for the BD of BRD9 (41), a member of
the SWI/SNF chromatin remodeling complex. AlphaScreen assays
confirmed GSK2801 interacted with the BRD9 BD. In contrast, a
second BAZ2A/B inhibitor, BAZ2-ICR (42), showed no interac-
tion with the BRD9 BD (Supplementary Fig. S2A–S2C). Neither
inhibitor displayed activity against the BET BD (Supplementary
Fig. S2D). Dose-dependent growth curves revealed that 3 mmol/L
GSK2801, which inhibits BAZ2A/B BDs but not the BRD9 BD,
produced partial growth suppression in combination with JQ1
compared with 10 mmol/L GSK2801 (Supplementary Fig. S2E).
Using RNAi targeting BRD9 in combination with JQ1 produced
enhanced growth suppression (Supplementary Fig. S2F and S2G).
Thus, inhibition of BRD9 by GSK2801 contributed to growth
Figure 1.
Drug synergy screens against BET and p300 BD inhibitors in TNBC cell lines. A, Schematic for screening approach. Cells were plated in 384-well plates and
treated 96 hours with 6 6 dose concentrations of library compound in combination with either JQ1 (BETi) or CPI-637 (p300i). Cell viability was measured with
CellTiter-Glo and drug synergy was quantified using Synergy Finder. B, Drug synergy rankings using Bliss scoring for JQ1 screens (performed in MDA-MB-231,
HCC1806, SUM-149(þ), MDA-MB-468, WHIM2, andWHIM12). Synergy scores represent the percent inhibition observed following combination treatment, which
exceeded the expected growth inhibition as calculated by the Bliss independencemodel. Values were generated by first calculating the mean Bliss score across
the full drug synergy matrix for each cell line (36 possible dose combinations). C and D, RNA-seq reads of BAZ2A and BAZ2B expression in primary TNBC patient
samples (C) versus 6 TNBC cell lines (D) used for screening. E–G,MDA-MB-231 growth curves transfected with nontargeting (NT) or BAZ2 siRNAs in combination
with 50 nmol/L JQ1. Error bars, SD, n¼ 6. P values were calculated using two-tailed t tests. H,Growth curves across multiple TNBC cell lines with 10 mmol/L
GSK2801. JQ1 doses were determined on the basis of the relative sensitivity of each cell line. MDA-MB-231: 30 nmol/L JQ1, SUM159: 100 nmol/L JQ1, SUM-149(þ)
andWHIM12: 300 nmol/L JQ1, HCC1806: 500 nmol/L JQ1. Error bars, SD, n¼ 6. P values comparing JQ1 versus combination drug treatment were calculated
using two-tailed t tests. I–K, 3D drug interaction landscapes produced using SynergyFinder between GSK2801 and JQ1/OTX015 or CPI-637 in the MDA-MB-231
cell line following 96-hour drug treatment. L–N,MDA-MB-231 growth curves with 100 nmol/L HY-16462 in combination with 100 nmol/L JQ1, 10 mmol/L CPI-637,
or 10 mmol/L GSK2801. Error bars, SD, n¼ 6. P values comparing BDi versus combination drug treatment were calculated using two-tailed t tests.
did not observe enhanced loss of BRD9 fromchromatin following
the addition of BAZ2i to the JQ1 treatment. This contrasts with
BRD2, whose dissociation from chromatin is greater with the
combinationofGSK2801þ JQ1 than seenwith JQ1alone (Fig. 2B
and C).
We observed a modest, but significant, increase in binding of
BETproteins andBRD9 to chromatin across ourChIP experiments
with single-agent GSK2801 treatment (Fig. 2A–C). The majority
of these peaks were classified at promoter regions and did not
correlate with regions most responsive to JQ1 treatment. BAZ2A,
BAZ2B, and BRD9 are members of chromatin remodeling com-
plexes and therefore, inhibition of their BDs may affect accessi-
bility of chromatin and result in the increased chromatin occu-
pancy of BRD2 andBRD9 thatweobserved following single-agent
GSK2801 treatment.
ChIP-seq in an additional TNBC cell line, SUM-159, also
showed significant loss of BRD2 from chromatin following com-
bination treatment (GSK2801 þ JQ1) relative to JQ1 alone
(Supplementary Fig. S3D), consistent with BAZ2A/B proteins
having a selective regulation of BRD2 relative to BRD4 and BRD9.
Importantly, knockdown of either BAZ2A or BAZ2B phenocopied
treatment with GSK2801 in combination with JQ1, with greater
displacement measured by ChIP-seq of BRD2 relative to JQ1
treatment alone (Fig. 2D and E). Loss of BRD2 chromatin occu-
pancy following combination BAZ2B RNAi/JQ1 treatment rela-
tive to JQ1 alonewas confirmed in theHCC1806 cell line (Fig. 2F;
Supplementary Fig. S3E).
Growth regulation in response to BRD2, BRD3, or BRD4
knockdown by siRNA
Knockdown of BET family proteins via RNAi in MDA-MB-
231 cells revealed loss of BRD2 expression alone had little effect
on growth, but induced strong growth inhibition in combina-
tion with GSK2801 (Fig. 2G). BRD3 loss of expression had no
effect on growth in the presence or absence of GSK2801
(Fig. 2H). BRD4 knockdown caused a partial growth arrest
alone and the addition of GSK2801 modestly enhanced growth
arrest (Fig. 2I). In an additional cell line, SUM-149(þ), we
observed a significant growth inhibition with BRD2 knock-
down alone and complete growth inhibition following the
addition of GSK2801 (Supplementary Fig. S3F). We confirmed
combined growth regulation between BRD2 and each BAZ
protein via RNAi knockdown. Coknockdown of BRD2 and
BAZ2A or BAZ2B enhanced growth inhibition of TNBC, with
strong growth inhibition observed when all three proteins were
lost (Fig. 2J–L), confirming inhibition of both BAZ2A and
BAZ2B contribute to drug synergy with BETi. The strong growth
inhibition observed with RNAi knockdown of BAZ2A/B con-
trasts with the partial growth inhibition observed using a
selective BAZ2A/B BD inhibitor, BAZ2-ICR, in combination
with JQ1 (Supplementary Fig. S2H). The reason for this is
unclear, except for the difference between loss of the protein
by knockdown versus the small-molecule BD inhibition of
BAZ2A/B in the absence of BRD9 BD inhibition. Consistent
with our screening data, knockdown of BRD2 did not enhance
the antiproliferative effect of an inhibitor targeting the BD of
CBP/p300 (SGC-CBP30) and a CDK9 inhibitor (HY-16462) in
MDA-MB-231 cells (Supplementary Fig. S3G–S3I). Cumula-
tively, the findings demonstrate that BRD2, BAZ2A/B, and
BRD9 control a chromatin network regulating cell growth
independent of P-TEFb.
inhibition observed with combination drug treatment (JQ1 þ 
GSK2801). Combining the selective BAZ2 BD inhibitor BAZ2-ICR 
with the selective BRD9 inhibitor BI-9564 elicited complete 
growth suppression in combination with JQ1, as seen with 
GSK2801 and JQ1 (Supplementary Fig. S2H). Western blots 
showed a BRD9-dependent reduction of c-MYC levels relative to 
JQ1 alone (Supplementary Fig. S2I), consistent with the role of 
BRD9 maintaining MYC expression and rapid cell proliferation as 
a member of the SWI/SNF complex (21).
Synergy screens were also performed with CPI-637, an inhibitor 
of the CBP/p300 BD, to assess the overlap of therapeutic vulner-
abilities to those found with BETi (Supplementary Data File 4). 
Reports of the significant activity of kinase inhibitors on BET 
BDs (43–45) led us to perform AlphaScreen assays across four 
doses (10 nmol/L, 100 nmol/L, 1 mmol/L, and 10 mmol/L) of our 
screening library to control for binding against the BET and CBP/
p300 BDs (Supplementary Data File 5). None of the screen hits 
displayed off-target activity at previously defined synergistic doses 
against either the BET or CBP/p300 BD (Supplementary Fig. S2J), 
which might otherwise account for drug synergy. We observed 
significant overlap between the BETi and CBP/p300i screening 
datasets, suggesting BET protein function is tightly linked to 
CBP/p300 acetyltransferase activity (Supplementary Fig. S2K). 
Uniquely, GSK2801 only displayed growth inhibition in combi-
nation with BETi, JQ1, and OTX015, and not the CBP/p300i 
CPI-637 (Fig. 1I–K). Furthermore, GSK2801 did not synergize 
with inhibition of CDK9, another member of the P-TEFb com-
plex, compared with p300i and BETi (Fig. 1L–N). This indicates a 
mechanism of synergy between GSK2801 and BETi, which is 
independent of P-TEFb–mediated transcriptional activation con-
trolled by BRD4.
Selective BRD2, 4 and 9 displacement from chromatin 
following treatment with BETi (JQ1), and BAZ2A/B BD 
inhibitor (GSK2801)
To gain a more comprehensive understanding of how BD 
proteins respond to GSK2801 and JQ1 treatment, we quanti-
fied BRD2, BRD4, and BRD9 on chromatin via ChIP-seq. Both 
BRD2 and BRD4, whose BDs bind JQ1, were significantly lost 
from chromatin following single-agent JQ1 treatment (Fig. 2A 
and B). There is a large degree of overlap between BET proteins 
at baseline with 38% of BRD4 peaks overlapping with BRD2 
and almost all BRD2 peaks (94%) overlapping with BRD4 
peaks. Despite this cooccupancy of chromatin peaks, relative 
to JQ1 treatment alone, only BRD2 but not BRD4 showed an 
enhanced loss from chromatin with JQ1 þ GSK2801 combi-
nation drug treatment (Fig. 2A and B). Classification of BRD2 
peaks showed GSK2801-dependent loss of BRD2 at both 
promoter and enhancer regions across the genome (Supple-
mentary Fig. S3A and S3B). This indicates the interaction of 
GSK2801 with BAZ2A/B and BRD9 BDs causes dissociation of 
BRD2 but not BRD4 from chromatin in the context of JQ1 
treatment.
ChIP-seq also was used to determine cooccupancy on chroma-
tin between BRD9 and BET proteins. We observed overlap 
between BRD4 and BRD9 independent of BRD2, but overlap 
between BRD2 and BRD9 was only observed when BRD4 was also 
present (Supplementary Fig. S3C). This suggests BRD9 is in 
chromatin complexes that include BET proteins, most notably 
BRD4. BRD9 was lost from chromatin following BETi despite the 
specificity of JQ1 for BET BDs and not the BRD9 BD (Fig. 2C). We
Figure 2.
BRD2 is displaced from chromatin following combination drug treatment. A–C, Levels of mapped BRD4 (A), BRD2 (B), and BRD9 (C) union peak density
following 48-hour treatment with 100 nmol/L JQ1, 10 mmol/L GSK2801, or the combination in MDA-MB-231 cells. Statistical significance was measured via two-
tailed, paired t tests. D and E, BRD2 peak density following transfection with 25 nmol/L nontargeting (NT), BAZ2A, or BAZ2B siRNA. MDA-MB-231 cells were
treated 48 hours following transfection 100 nmol/L JQ1. Statistical significance was measured via two-tailed, paired t tests. F, BRD2 density following
transfection with 25 nmol/L nontargeting or BAZ2B siRNA alone and in combination with 500 nmol/L JQ1 treatment in the HCC1806 cell line. Statistical
significance was measured via two-tailed, paired t tests. G–I,MDA-MB-231 growth curves transfected with GAPDH siRNA as a control or 25 nmol/L BRD2 siRNA
(G), 25 nmol/L BRD3 siRNA (H), and 1 nmol/L BRD4 siRNA (I) alone and in combination with 10 mmol/L GSK2801. Error bars, SD, n¼ 6. P values were calculated
using two-tailed t tests. J–L,MDA-MB-231 cells transfected with 25 nmol/L nontargeting or BRD2 siRNA alone and in combination with 25 nmol/L BAZ2A siRNA
(J), BAZ2B siRNA (K), or BAZ2Aþ BAZ2B siRNAs (L). Error bars, SD, n¼ 6. P values were calculated using two-tailed t tests.
treatment (Fig. 3L–O; Supplementary Fig. S4F andS4G); however,
BRD4 density was maintained or only slightly decreased relative
to JQ1 treatment alone. These genes were transcriptionally
repressed with JQ1 and further repressed with addition of
GSK2801 (Supplementary Fig. S4H). GSEA of RNA-seq data
from MDA-MB-231, HCC1806, and SUM-159 cells (Supple-
mentary Data File 6) showed loss of transcriptional programs
that are regulated by ETS transcription factors including c-MYC
targets, core serum response, E2F targets, and G2M checkpoint
in response to combination drug treatment (Supplementary
Fig. S4I). Cell-cycle analysis via propidium iodide staining
revealed G1 arrest in response to JQ1, which was enhanced
with combination drug treatment (Supplementary Fig. S4J
and S4K). These data indicate BRD2 regulates transcriptional
programs necessary to drive cell growth, specifically those
regulated by ETS transcription factors.
BRD2 is localized in the nucleolus and nucleoplasm of
TNBC cells
Further inspection of GSEA revealed an enrichment of ribo-
some biogenesis and rRNA processing gene sets in untreated
samples relative to cells treated with combination GSK2801 þ
JQ1 (Fig. 4A). In addition, we observed enrichment of chro-
matin silencing gene sets in combination-treated cells, specif-
ically silencing at ribosomal DNA. All stages of rRNA transcrip-
tion, processing, and ribosome biogenesis occur in the nucle-
olus. Notably, transcription of rDNA is the rate-limiting step of
ribosome biogenesis and therefore serves as a rheostat of
translational activity in cells. Silencing of rDNA regulates rep-
licative senescence during aging (47, 48), and nucleolar repres-
sion is sufficient to initiate and maintain senescence in tumor
cells (49, 50). We tested the localization of each BET protein to
the nucleolus via immunofluorescence (Fig. 4B). BRD2 was the
only BET protein that localized to both the nucleoplasm and
nucleolus. BRD3 was largely present in the nucleoplasm and
excluded from the nucleolus, and BRD4 was present in both the
cytoplasm and nucleoplasm but also excluded from the nucle-
olus (Fig. 4B; Supplementary Fig. S5A and S5B). Quantification
of staining confirmed BRD2 was significantly greater in the
nucleolus among the BET proteins (Fig. 4C). Furthermore,
BRD2 displayed greater staining density in the nucleolus when
compared with its nucleoplasmic staining, which was not seen
with BRD3 or BRD4 (Fig. 4D).
Dual suppression of BAZ2/BRD9 and BRD2 BDs suppresses
rDNA transcription
Consistent with our immunofluorescence data, BRD2 but not
BRD4 ChIP density aligned to the coding region of the rDNA
repeat (Fig. 5A; Supplementary Fig. S6A and S6B). We observed
modest changes in BRD2 occupancy at rDNA following single-
agent treatment with either JQ1 or GSK2801; however, BRD2was
significantly lost from the rDNA coding region following com-
bination drug treatment with greatest loss at the rDNA promoter
and start of the 18S exon (Fig. 5B; Supplementary Fig. S6B).
Knockdown of BRD2, but not BRD4, resulted in transcriptional
loss of the 45S rRNA precursor observed by qPCR (Fig. 5C).
Interestingly, rDNA is transcribed by RNA polymerase I and so
these data may explain, in part, why we observed amechanism of
drug synergy between GSK2801 and JQ1 independent of P-TEFb
complex regulation, which exclusively regulates pause-release of
RNA polymerase II. Indeed, combination drug treatment resulted
Displacement of BRD2 from chromatin following combination 
drug treatment occurs at genomic loci associated with ETS 
transcription factors
We sought to understand the functional consequence of 
BRD2 loss from chromatin in response to combination drug 
treatment by assessing the correlation between changes in 
BRD2 chromatin occupancy and gene transcription. RNA-seq 
revealed 1,257 genes were transcriptionally downregulated 
two-fold in response to JQ1 in MDA-MB-231 cells. Most 
JQ1-responsive genes were further downregulated following 
the addition of GSK2801, including 235 genes downregulated 
two-fold or greater relative to JQ1 treatment alone (Fig. 3A). We 
next measured the proximity of BRD2 peaks to the 235 "com-
bination transcriptionally-responsive" genes. Promoter and 
putative enhancer BRD2 peaks were defined within 5 kb or 
200 kb of the gene promoter, respectively. Of the 235 combi-
nation-responsive genes, 117 had both a promoter and enhanc-
er BRD2 peak, 7 only had measurable BRD2 at their promoter, 
24 had only BRD2 enhancers, and 27 had no measurable BRD2 
peaks within 200 kb of their promoter (Fig. 3B). Metagene plots 
of BRD2 and BRD4 at the transcription start site (tss) of 
combination-responsive genes showed both BET proteins were 
lost following JQ1 treatment, but only BRD2 was significantly 
lost with the addition of GSK2801 relative to JQ1 alone 
(Fig. 3C–F). Similar plots of enhancers showed consistent 
results with BRD2 density lost following combination drug 
treatment but not BRD4 density (Supplementary Fig. S4A and 
S4B). Waterfall plots measuring the fold change in BRD2 and 
BRD4 density following combination treatment relative to JQ1 
revealed a higher resolution view of BET protein dynamics at 
the tss of individual responsive genes. BRD2 reads were lost at 
the majority of tss, whereas BRD4 displayed a larger range of 
responses, which did not mirror those of BRD2 (Supplementary 
Fig. S4C). In some cases, BRD4 was lost from the promoter of 
responsive genes; however, in these cases BRD2 was often 
lost to a greater degree. We were able to validate BAZ2A/B–
dependent  displacement of BRD2 at the  tss of combination-
responsive genes using RNAi knockdown of BAZ2A/B proteins 
in the presence of JQ1 (Fig. 3G and H). Similar to the global 
analysis (Fig. 2D and E), BAZ2B knockdown resulted in greater 
displacement of BRD2 from tss of responsive genes compared 
with BAZ2A suggesting BAZ2B is primarily responsible for 
BRD2 regulation at these genes. This analysis validates a 
BAZ2A/B–dependent loss of BRD2 at genomic loci proximal 
to transcriptionally responsive genes following coinhibition of 
BAZ2 and BET BDs.
Consensus-binding sequence analysis of BRD2 ChIP peaks 
using Homer software determined significant enrichment of 
binding motifs for class 1 ETS transcription factors and the 
structural protein YY1 across three TNBC cell lines: MDA-MB-
231, SUM-159, and HCC1806 (Fig. 3I–K). Consistent with our 
results, a recent study found enrichment of ETS-binding motifs at 
BRD2-occupied loci in T cells as well as motifs for the structural 
protein CTCF (46). ETS-binding motifs were also enriched at a 
subset of genomic loci where BRD2 is significantly lost following 
combination JQ1 þ GSK2801 drug treatment (Supplementary 
Fig. S4D and S4E). Of the 235 responsive genes, 85 contained an 
ETS-binding motif within 200 bp of the tss. We observed almost 
complete loss of BRD2 from multiple ETS-regulated genes critical 
for cell-cycle progression including cyclin B1, Aurora kinase A, 
E2F8, PLK1, LMNB1, and MAPK13 following combination drug
Figure 3.
BRD2 is displaced from ETS-regulated gene promoters and enhancers following combination treatment with GSK2801 and JQ1.A, Long tail plot ofMDA-MB-231
genes downregulatedtwo-fold following 72-hour treatment with 100 nmol/L JQ1. Values represent mRNA fold change between treatment with 10 mmol/L
GSK2801þ JQ1 versus JQ1 alone. Genes highlighted in gray were downregulatedtwo-fold in combination-treated cells relative to JQ1 alone. B,Association of
BRD2 peaks with "combination-responsive" genes in DMSO treated MDA-MB-231 cells. C–F,Metagene plots of BRD2 (C) and BRD4 (E) density at tss of
"combination-responsive" genes. MDA-MB-231 cells were treated 48 hours with DMSO, 10 mmol/L GSK2801, 100 nmol/L JQ1, or the combination. Bar plots, total
read counts of BRD2 (D) or BRD4 (F) 1 kb of the tss. P values were calculated via two-tailed, paired t tests (G–H) Metagene plots of BRD2 density at tss of
"combination-responsive" genes following transfection with BAZ2A (G) or BAZ2B (H) siRNA. MDA-MB-231 cells were treated 48 hours with and without 100
nmol/L JQ1 following transfection. I–K,Motif analysis of BRD2 binding in DMSO-treated samples of MDA-MB-231 (I), SUM-159 (J), and HCC1806 (K) cell lines.
L–O, BRD2 and BRD4 ChIP-seq density tracks following 48-hour treatment with DMSO, 10 mmol/L GSK2801, 100 nmol/L JQ1, or the combination in MDA-MB-231
cells. Black bars, ETS-binding motifs. Bar plots, total read counts of BRD2 or BRD4 1 kb of the tss.
in loss of the 45S rRNA specifically in combination-treated
samples across multiple cell lines (Fig. 5D–F). We performed
S35 methionine labeling experiments to quantify global transla-
tion in response to drug in MDA-MB-231 cells. Although these
results largely mirrored cell growth, we saw marked loss of S35
methionine incorporation following combinationdrug treatment
(Fig. 5G). These data support a novel role of BRD2 in positively
regulating rRNA transcription and suggest loss of rRNA, and
subsequent translation, during combination drug treatment
contributes to synergistic growth inhibition.
BAZ2A is present in the nucleolus and nucleoplasm and is
coregulated with BET BD proteins
Because of the lack of commercial antibodies with selective
specificity for BAZ proteins needed for ChIP, we used CRISPR to
engineer a C-terminal in-frame V5 epitope tag in the BAZ2A gene
in MDA-MB-231 cells (Supplementary Fig. S7A and S7B). The
presence of multiple alternative tss and lack of C-terminal
sequence required for guide RNA design prohibited us from
successfully tagging BAZ2B. Immunoblotting confirmed
BAZ2A-V5 was expressed at similar levels as BAZ2A protein in
parental cells (Fig. 6A). ChIP-seq using a V5 antibody revealed
BAZ2A-V5 bound the coding region of rDNA in a similar pattern
as seen with BRD2 but not BRD4 or BRD9 (Fig. 6B). The presence
of BAZ2A-V5 in the nucleolus is consistent with the published
function of BAZ2A (TIP5) as a member of the nucleolar remodel-
ing complex. These findings are consistent with BAZ2A being
associated with transcriptional complexes containing BRD2with-
in the nucleolus.
Immunofluorescent imaging confirmed BAZ2A-V5 staining in
the nucleolus with significantly stronger staining density of
BAZ2A-V5 in the nucleoplasm (Fig. 6C and D). Quantification
Figure 4.
BRD2 is the only BET protein localized to the nucleolus.A, GSEA of MDA-MB-231, HCC1806, and SUM-159 RNA-seq datasets treated 72 hours with 10 mmol/L
GSK2801 and 100 nmol/L JQ1 (MDA-MB-231 and SUM-159) or 500 nmol/L JQ1 (HCC1806). Orange values, ribosome biogenesis or rRNA processing gene
signatures. Positive enrichment scores, gene sets enriched in DMSO. Negative enrichment scores, gene sets enriched in GSK2801þ JQ1–treated samples. B,
Immunofluorescent staining of BET proteins with fibrillarin (nucleolar marker) and Hoechst (nuclear marker). C and D,Quantification of nucleolar versus
nucleoplasmic staining intensity of BET proteins. A one-way ANOVAwas conducted to compare intensity of BET protein staining, P < 2e-16 for C and D.
Post hoc comparisons were made using the Tukey HSD test.
Combination treatment with BAZ2/BRD9 and BET BD
inhibitors induces senescence and apoptosis
To further characterize the cellular phenotype in response to
combination drug treatment, we performed beta-galactosidase
(b-gal) staining of TNBC cell lines grown in 2D cultures treated
with drug for 96 hours. Combination drug treatment resulted in a
higher percentage of b-gal–positive cells relative to JQ1 alone
(Fig. 7A–D). Again, treatment with a selective BAZ2A/B BD
Figure 5.
Displacement of BRD2 from the rDNA repeat coincides with transcriptional repression of rRNA. A, Alignment of BRD2 ChIP-seq reads to the rDNA repeat in
MDA-MB-231 cells. B, Response of BRD2 density on rDNA in response to 48-hour treatment with DMSO, 10 mmol/L GSK2801, 100 nmol/L JQ1, or the combination
in MDA-MB-231 cells. C, qPCRmeasuring 45S rRNA following 96-hour transfection with nontargeting (NT), BRD2, or BRD4 siRNA in MDA-MB-231 cells. Error bars,
SD, n¼ 3. P values were calculated using two-tailed t tests. D and E, qPCRmeasuring 45S rRNA in SUM-159 (D) and MDA-MB-231 (E) cells following 96-hour
treatment with DMSO, 10 mmol/L GSK2801, 100 nmol/L JQ1, or the combination. Error bars, SD, n¼ 3. P values were calculated using two-tailed t tests. F, qPCR
measuring 45S rRNA in theWHIM12 cell line following 96-hour treatment with 500 nmol/L JQ1 10 mmol/L BAZ2-ICR and 300 nmol/L BI-9564. Error bars, SD,
n¼ 3. P values were calculated using two-tailed t tests. G, S35 labeling of protein production in MDA-MB-231 cells following 72-hour treatment with 10 mmol/L
GSK2801, 100 nmol/L JQ1, or the combination. A total of 100 mg/mL cycloheximide treatment was included as a positive control.
of staining revealed that, on average, only 10% of total BAZ2A-V5 
staining in the nucleus was restricted to the nucleolus (Fig. 6E). 
Quantification of global BAZ2A-V5 chromatin occupancy 
revealed a significant loss of BAZ2A-V5 from chromatin following 
inhibition of its BD by GSK2801 (Fig. 6F). We also observed 
significant global displacement of BAZ2A following treatment 
with the BETi JQ1, suggesting BAZ2A is coregulated with BET BD 
proteins such as BRD2 on chromatin.
inhibitor, BAZ2-ICR, induced a partial response and it was not
until the addition of the BRD9 inhibitor, BI-9564, that we saw
a similar percentage of b-gal–positive cells compared with
GSK2801. This confirms that although BAZ2A/B inhibition is
contributing to synergistic growth inhibition, the effect of
GSK2801 on BRD9 also contributes to drug synergy. Positive
b-gal staining suggests that cells are entering a senescent state
following combination drug treatment. We looked at which
drivers of senescence signaling were responsible for the pheno-
type. All cell lines screened contain TP53 mutations common to
TNBC, andmost cell lines also contain deletion or transcriptional
silencing of CDKN2A (p16; Supplementary Fig. S8A). This left
CDKN1A (p21) andRB1, the retinoblastoma tumor suppressor as
candidate regulators of senescence. RNA-seq data showed induc-
tion of p21 transcript levels following a dose of JQ1 that induces
modest b-gal staining (Supplementary Fig. S8B). Western blots
in multiple cell lines confirmed induction of p21 protein levels
and decrease in phospho-Rb in combination-treated samples
(Fig. 7E–G; Supplementary Fig. S8C and S8D).While knockdown
of p21 via RNAi was able to rescue JQ1 growth inhibition, it only
partially rescued growth inhibition of combination drug–treated
cells (Fig. 7H). These data suggest induction of p21 only partially
regulates the senescent state of cells treated with JQ1 and
GSK2801. It is therefore likely treatment with BAZ2A/B/BRD9i
and BETi results in senescence via multiple mechanisms. First,
inhibition of cell-cycle gene transcription results in G1 arrest and
induction of p21. Secondly, this growth arrest is likely enhanced
by nucleolar suppression and translational silencing following
loss of BRD2 from the rDNA promoter.
GSK2801 has poor pharmacokinetics in mice combined with a
relatively high IC50 for the BAZ2/BRD9 BDs (41), so we tested
combination drug treatment in 3D-spheroid models (Fig. 7I–L;
Supplementary Fig. S8E and S8F). Breast cancer cells expressing
RFP were cocultured with RMFs expressing GFP. We observed a
dramatic reduction in breast tumor cell fluorescence following
10-day combination treatment compared with either single agent
Figure 6.
BAZ2A is coregulated with BRD2 in the nucleolus and nucleoplasm.A,Western blot analysis of MDA-MB-231 cell lysate expressing wild-type BAZ2A versus
BAZ2A-V5. B,Alignment of BAZ2A-V5, BRD2, BRD4, and BRD9 ChIP-seq reads to the rDNA repeat in MDA-MB-231 cells. C, Representative images of
immunofluorescent staining of BAZ2A-V5 with fibrillarin (nucleolar marker). D and E,Quantification of nucleolar versus nucleoplasmic staining intensity of V5 in
approximately 200 individual cells. F, Levels of BAZ2A-V5 union peak density following 48-hour treatment with 100 nmol/L JQ1, 10 mmol/L GSK2801, or the
combination in MDA-MB-231 cells.
Figure 7.
Combined GSK2801 and JQ1 treatment induces senescence and apoptosis in TNBC cell lines. A–D, Senescence-associated b-gal staining in HCC1806 (A–B) and
WHIM12 (C–D) cell lines following 96-hour drug treatment. Cells were dosed with 10 mmol/L GSK2801, 10 mmol/L BAZ2-ICR, 1 mmol/L BI-9564, and either 300
nmol/L JQ1 (HCC1806) or 500 nmol/L JQ1 (WHIM12). E–G,Western blots of MDA-MB-231 (E), SUM-149(þ) (F), andWHIM12 (G) cell lysates following 72-hour
treatment with 10 mmol/L GSK2801 and either 100 nmol/L JQ1 (MDA-MB-231), 300 nmol/L JQ1 (SUM-149(þ)), or 500 nmol/L JQ1 (WHIM12). H,MDA-MB-231 cells
transfected with 25 nmol/L nontargeting (NT) or p21 siRNA alone and in combination with 10 mmol/L GSK2801 and 50 nmol/L JQ1. Error bars, SD, n¼ 6. I–L, 3D
spheroids with SUM-149(þ) andWHIM12 cell lines cocultured with RMFs treated 10 days with GSK2801 and JQ1. Tumor cell fluorescence was measured at
endpoint and cell viability was measured with CellTiter-Glo 3D reagent, Error bars, SD, n¼ 3. P values were calculated using two-tailed t tests.
Genes regulated by ETS transcription factors and the 45S rDNA
promoter are selectively targeted by GSK2801 in combination
with JQ1 for loss of BRD2, as defined by ChIP assay. Targeting of
ETS-regulated genes and ribosomal RNA transcription using
GSK2801 þ JQ1 gave a strong antiproliferative response com-
bined with the induction of proapoptotic caspase-3 activity and
PARP cleavage in 3Dcultures. To date, themost tractable inhibitor
of the BAZ2A/B BD is GSK2801, which also binds the BRD9 BD.
Inhibition of the BRD9 BD clearly contributed to the antiproli-
ferative actionof the JQ1þGSK2801 combination treatment.Use
of this tool compound enabled us to establish inhibition of
BAZ2/BRD9 BDs as an effective means to block BRD2-driven
transcription in combination with BETi in TNBC 2D cultures and
3D-spheroid models. Why senescence is observed in 2D cultures
and apoptosis observed in 3Dcultures is unclear, butmost likely is
related to the adherence and cell interaction differences in the two
models.
TNBCs do not contain significant mutations or copy-number
alterations in BAZ2A, BAZ2B, or BRD9. Our study is the first to
highlight BAZ2A/B and BRD9 as targetable vulnerabilities in
TNBC in the context of BETi. Noncanonical functions of BAZ2A
have been previously characterized in driving cancer phenotypes.
Overexpression of BAZ2A in prostate cancer predicts disease
recurrence and, in this context, BAZ2A was shown to interact
with EZH2 and modulate expression of protein-coding genes in
the nucleoplasm (51). BAZ2A also interacts with TCF7L2 to drive
b-catenin signaling and promote growth in hepatocellular carci-
noma (52). There is less direct evidence for BAZ2B's involvement
in cancer but hypomethylation of the BAZ2B gene is associated
with poor outcome in acute lymphoblastic leukemia (53), sug-
gesting it may play a functional role in driving tumor growth and
progression. The distinct functional roles of BAZ2A in cancer
suggest inhibition of its BD may result in tumor-specific toxicity.
Together our findings present coinhibition of BAZ2A/B and BRD9
BDs in combination with BET protein BD inhibition as an
effective strategy to block nucleoplasmic and nucleolar BRD2-
regulated transcription for growth arrest, and induction of apo-
ptosis of TNBC.
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alone in SUM-149(þ) and WHIM12 cell lines (Fig. 7I–L). This was 
consistent with ATP measurements using CellTiter-Glo 3D 
reagent, which showed diminished cell viability in the combina-
tion-treated spheroids. There was no reduction in fluorescence 
from the normal breast fibroblast population following drug 
treatment, indicating a selective loss of tumor cell viability (Sup-
plementary Fig. S8E and S8F). Monoculture spheroids established 
using only SUM-149(þ) tumor cells displayed cleaved caspase-3 
and cleaved PARP following 36-hour treatment with combination 
GSK2801 þ 100 nmol/L or 300 nmol/L JQ1 (Supplementary 
Fig. S8G). Apoptosis was only present in spheroids treated with 
both drugs and not with either JQ1 or GSK2801 alone. These 
results were consistent with CellTiter-Glo measurements, which 
showed dose-dependent reduction in cell viability with increasing 
doses of JQ1 in combination with GSK2801 (Supplementary 
Fig. S8H). These data highlight coinhibition of BAZ2/BRD9 and 
BET BDs as an effective strategy to induce apoptosis in TNBC.
Discussion
Ten BET BD inhibitors are currently in different phases of 
clinical trials for multiple tumor types including breast cancer 
(ClinicalTrials.gov). Despite some dose-dependent toxicity such 
as thrombocytopenia, the tolerability of different BETi in patients 
suggests that synergistic combination therapies may be practical. 
We previously showed the relevance of synergistic combination 
therapies with BETi in both HER2þ and TNBC preclinical models, 
demonstrating that BETi effectively blocks epigenetic transcrip-
tional reprogramming making targeted kinase inhibitors, lapati-
nib and trametinib, more durable in their inhibition of tumor 
growth in vitro and in vivo (6, 7). Our BETi screens identified 
inhibitors of MEK1/2-ERK1/2, CDK9, CBP/p300, and Aurora 
kinase as synergistic drug combinations with multiple TNBC cell 
lines. Trametinib and selumetinib are FDA-approved MEK1/2 
inhibitors and there are multiple Aurora kinase inhibitors 
currently in all phases of clinical trials, alone and in different 
combinations with chemotherapy and targeted therapeutics 
(ClinicalTrials.gov). Therefore, BETi combination trials with 
MEK1/2 or Aurora kinase inhibitors could be initiated quickly 
because of the substantial knowledge of pharmacology and 
tolerability of each in patient trials.
The BDs of BAZ2/BRD9 were identified as novel targets for 
synergy with BETi to produce antiproliferative responses for 
multiple TNBC cell lines. The synergy seen with GSK2801 was 
regulated by a different mechanism than inhibitors targeting 
CBP/p300 and CDK9 of the P-TEFb transcriptional regulatory 
complex that is associated with BRD4. Instead, the uniqueness of 
this combination treatment is selective enhancement of BRD2 
chromatin release in response to inhibition of BAZ2/BRD9 BDs.
While our data support a mechanism of synergy by which BRD9 
modulates cell growth through regulation of MYC expression, it is 
possible BRD9 is involved in regulation of BRD2 or BAZ2 pro-
teins. ChIP data show overlap between BRD2 and BRD9 peaks at 
regions where BRD2 is responsive to drug treatment. However, we 
do not observe the same displacement of BRD9 from chromatin 
following combination drug treatment as we see with BRD2. 
BRD9 is released from chromatin in response to JQ1 treatment 
alone, even though JQ1 does not bind the BRD9 BD, demon-
strating the complexity of the BD-encoded proteins and their 
interaction with chromatin.
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